+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Modulation of eosinophil recruitment in the rat by the platelet-activating factor (PAF) antagonist, BN 52021, the somatostatin analog, BIM 23014, and by cyclosporin A

Modulation of eosinophil recruitment in the rat by the platelet-activating factor (PAF) antagonist, BN 52021, the somatostatin analog, BIM 23014, and by cyclosporin A

Prostaglandins 37(3): 345-357

The factors responsible for in vivo eosinophil recruitment are poorly defined, although T-lymphocytes appear to be involved in the etiology of eosinophilia. In order to clarify this relationship, we studied the modulation of eosinophil mobilization in the rat after immune challenge, by chronic treatment with the PAF-antagonist, BN 52021, the somatostatin analog, BIM 23014 and with Cyclosporin A (CsA). In rats made hypereosinophilic by pretreatment with cyclophosphamide or sephadex, a significant increase of the eosinophil count in blood and peritoneal fluid was induced by anaphylactic reaction. CsA totally abolished both hypereosinophilia and peritoneal eosinophil infiltration. BIM 23014 also, significantly reduced the circulating eosinophils (-68%, p less than 0.001) and cell infiltration (-86%, p less than 0.05). In contrast, BN 52021 decreased peritoneal eosinophil recruitment, while having relatively little effect on circulating cells. CsA and somatostatin are known to affect T-cell proliferation, and as T-cells are involved in the differentiation of hematopoietic cells into eosinophils, these drugs could decrease eosinophil availability for recruitment. In contrast, the PAF antagonist may act by inhibiting PAF-induced eosinophil chemotaxis, providing a more specific inhibition of this process than that exerted by CsA, BIM 23014 and other immunosuppressive agents.

Please choose payment method:

(PDF emailed within 0-6 h: $19.90)

Accession: 040718823

Download citation: RISBibTeXText

PMID: 2748916

DOI: 10.1016/0090-6980(89)90005-1

Related references

Effect of cyclosporin A and the platelet-activating factor (PAF) antagonist, BN 52021, on PAF- and antigen- induced bronchoconstriction in the guinea-pig. Biochemical and Biophysical Research Communications 163(1): 118-123, 1989

The effect of platelet activating factor and bn 52021 a platelet activating antagonist on the biology of lymphocytes. FASEB Journal 2(5): ABSTRACT 5482, 1988

Proof of the involvement of paf acether platelet activating factor in pulmonary complex immune systems using a specific paf acether platelet activating factor receptor antagonist bn 52021. International Journal of Immunopharmacology 7(3): 385, 1985

The effects of platelet activating factor acether on the cardiovascular system and their inhibition by a new highly specific platelet activating factor acether receptor antagonist bn 52021. Pharmacological Research Communications 18(8): 717-738, 1986

Modulation by drugs of eosinophil recruitment induced by immune challenge in the rat. Possible roles of interleukin 5 and platelet-activating factor. International Archives of Allergy and Applied Immunology 88(1-2): 216-221, 1989

Activity of a novel thienodiazepine derivative as a platelet-activating factor antagonist in guinea pig lungs. Effects on platelet-activating factor and allergen induced eosinophil accumulation. Arzneimittel-Forschung 41(3): 224-227, 1991

Bleomycin-induced lung injury in the rat: effects of the platelet-activating factor (PAF) receptor antagonist BN 52021 and platelet depletion. Environmental Health Perspectives 85: 65-69, 1990

BN 52021: a platelet activating factor antagonist for preventing post-transplant renal failure. A double-blind, randomized study. The BN 52021 Study Group in Renal Transplantation. Annals of Internal Medicine 121(5): 345-347, 1994

Cardiac ultrastructural effects of the platelet-activating factor and its antagonist BN 52021. Experimental and Toxicologic Pathology 47(6): 463-470, 1995

Platelet-activating factor antagonist, BN-52021 protects against cis-diamminedichloroplatinum nephrotoxicity in the rat. Renal Failure 12(3): 171-176, 1990

Effect of BN 52021, a platelet activating factor antagonist, on dithranol-induced inflammation. British Journal of Dermatology 122(4): 539-544, 1990

Electrophysiological effects of platelet activating factor paf and its antagonist bn 52021 in cardiac preparations. European Journal of Pharmacology 183(4): 1240-1241, 1990

Cardiac electrophysiologic and ultrastructural effects of platelet-activating factor and its antagonist BN 52021. Transplantation Proceedings 27(5): 2819-2820, 1995

Anti-anaphylactic properties of BN 52021: a potent platelet activating factor antagonist. Advances in Experimental Medicine and Biology 215: 215-235, 1987

The effect of the platelet activating factor antagonist bn 52021 on the hyperglycemia induced by alloxan. Prostaglandins 34(2): 188, 1987